Left ventricular assist device-associated driveline infections as a specific form of complicated skin and soft tissue infection/acute bacterial skin and skin structure infection - issues and therapeutic options.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
12 Dec 2023
12 Dec 2023
Historique:
medline:
12
12
2023
pubmed:
12
12
2023
entrez:
12
12
2023
Statut:
aheadofprint
Résumé
This review comments on the current guidelines for the treatment of wound infections under definition of acute bacterial skin and skin structure infections (ABSSSI). However, wound infections around a catheter, such as driveline infections of a left ventricular assist device (LVAD) are not specifically listed under this definition in any of the existing guidelines. Definitions and classification of LVAD infections may vary across countries, and the existing guidelines and recommendations may not be equally interpreted among physicians, making it unclear if these infections can be considered as ABSSSI. Consequently, the use of certain antibiotics that are approved for ABSSSI may be considered as 'off-label' for LVAD infections, leading to rejection of reimbursement applications in some countries, affecting treatment strategies, and hence, patients' outcomes. However, we believe driveline exit site infections related to LVAD can be included within the ABSSSI definition. We argue that driveline infections meet the criteria for ABSSSI which would enlarge the 'on-label' antibiotic armamentarium for treating these severe infections, thereby improving the patients' quality of life.
Identifiants
pubmed: 38085707
doi: 10.1097/QCO.0000000000000999
pii: 00001432-990000000-00129
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023; 118:3272–3287.
Marasco SF, McDonald C, McGiffin DC. Chapter 15 – Surgical implantation. In: Gregory SD, Stevens MC, Fraser JF, editos. Mechanical circulatory and respiratory support. Academic Press; 2017:469–494.
Bernhardt AM, Schlöglhofer T, Lauenroth V, et al. Prevention and early treatment of driveline infections in ventricular assist device patients – the destine staging proposal and the first standard of care protocol. J Crit Care 2020; 56:106–112.
Qu Y, Peleg AY, McGiffin D. Ventricular assist device-specific infections. J Clin Med 2021; 10:453.
O’Horo JC, Abu Saleh OM, Stulak JM, et al. Left ventricular assist device infections: a systematic review. ASAIO J 2018; 64:287–294.
Gordon RJ, Weinberg AD, Pagani FD, et al. Prospective, multicenter study of ventricular assist device infections. Circulation 2013; 127:691–702.
Lumish HS, Cagliostro B, Braghieri L, et al. Driveline infection in left ventricular assist device patients: effect of standardized protocols, pathogen type, and treatment strategy. ASAIO J 2022; 68:1450–1458.
Nienaber JJ, Kusne S, Riaz T, et al. Clinical manifestations and management of left ventricular assist device-associated infections. Clin Infect Dis 2013; 57:1438–1448.
Sharma V, Deo SV, Stulak JM, et al. Driveline infections in left ventricular assist devices: implications for destination therapy. Ann Thorac Surg 2012; 94:1381–1386.
Topkara VK, Kondareddy S, Malik F, et al. Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era. Ann Thorac Surg 2010; 90:1270–1277.
Seretny J, Pidborochynski T, Buchholz H, et al. Decreasing driveline infections in patients supported on ventricular assist devices: a care pathway approach. BMJ Open Qual 2022; 11:e001815.
Zinoviev R, Lippincott CK, Keller SC, et al. In full flow: left ventricular assist device infections in the modern era. Open Forum Infect Dis 2020; 7:ofaa124.
Toba FA, Akashi H, Arrecubieta C, et al. Role of biofilm in Staphylococcus aureus and Staphylococcus epidermidis ventricular assist device driveline infections. J Thorac Cardiovasc Surg 2011; 141:1259–1264.
Leuck A-M. Left ventricular assist device driveline infections: recent advances and future goals. J Thorac Dis 2015; 7:2151–2157.
Kusne S, Mooney M, Danziger-Isakov L, et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Heart Lung Transplant 2017; 36:1137–1153.
Smith EM, Franzwa J. Chronic outpatient management of patients with a left ventricular assist device. J Thorac Dis 2015; 7:2112–2124.
Hasanpour AH, Sepidarkish M, Mollalo A, et al. The global prevalence of methicillin-resistant staphylococcus aureus colonization in residents of elderly care centers: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2023; 12:4.
Sunderkötter C, Becker K, Eckmann C, et al. Calculated initial parenteral treatment of bacterial infections: skin and soft tissue infections. GMS Infect Dis 2020; 8:Doc11.
Sunderkötter C, Becker K, Eckmann C, et al. S2k guidelines for skin and soft tissue infections excerpts from the S2k Guidelines for “calculated initial parenteral treatment of bacterial infections in adults - update 2018”. J Dtsch Dermatol Ges 2019; 17:345–369.
Pollack CV Jr, Amin A, Ford WT Jr, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med 2015; 48:508–519.
US Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Available at: https://www.fda.gov/files/drugs/published/Acute-Bacterial-Skin-and-Skin-Structure-Infections---Developing-Drugs-for-Treatment.pdf [Accessed 12 December 2022].
Esposito S, Bassetti M, Concia E, et al. Diagnosis and management of skin and soft-tissue infections (SSTI). a literature review and consensus statement: an update. J Chemother 2017; 29:197–214.
Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147–159.
Moffarah AS, Al Mohajer M, Hurwitz BL, et al. Skin and soft tissue infections. Microbiol Spectr 2016; 4:14–25.
Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis 2016; 29:109–115.
Ramakrishnan K, Salinas RC, Agudelo Higuita NI. Skin and soft tissue infections. Am Fam Physician 2015; 92:474–483.
Eckmann C, Tulkens PM. Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics. J Antimicrob Chemother 2021; 76:iv9–iv22.
Miller LG, Eisenberg DF, Liu H, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings. BMC Infect Dis 2015; 15:362.
Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med 2007; 74: (Suppl 4): S21–28.
Koval CE, Thuita L, Moazami N, et al. Evolution and impact of drive-line infection in a large cohort of continuous-flow ventricular assist device recipients. J Heart Lung Transplant 2014; 33:1164–1172.
Pavlovic NV, Randell T, Madeira T, et al. Risk of left ventricular assist device driveline infection: a systematic literature review. Heart Lung 2019; 48:90–104.
Schaffer JM, Allen JG, Weiss ES, et al. Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation. J Heart Lung Transplant 2011; 30:164–174.
Belz S, Fisquet S, Ahuja A, et al. Incidence of infection and antimicrobial consumption in ventricular assist device (VAD) recipients at the Prince Charles Hospital (Tpch): a retrospective analysis. Heart Lung Circ 2020; 29:1234–1240.
Patel S, Nicholson L, Cassidy CJ, et al. Left ventricular assist device: a bridge to transplant or destination therapy? Postgrad Med J 2016; 92:271–281.
Kavanagh KT, Cormier LE. Success and failures in MRSA infection control during the COVID-19 pandemic. Antimicrob Resist Infect Control 2022; 11:118.
Weber RE, Fleige C, Layer F, et al. Determination of a tentative epidemiological cut-off value (Ecoff) for dalbavancin and Enterococcus faecium. Antibiotics 2021; 10:915.
Hitzenbichler F, Mohr A, Camboni D, et al. Dalbavancin as long-term suppressive therapy for patients with gram-positive bacteremia due to an intravascular source—a series of four cases. Infection 2021; 49:181–186.
Howard-Anderson J, Pouch SM, Sexton ME, et al. Left ventricular assist device infections and the potential role for dalbavancin: a case report. Open Forum Infect Dis 2019; 6:ofz235.
Pant N, Wallis SC, Roberts JA, et al. In vitro effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation. J Antimicrob Chemother 2022; 77:1041–1044.
Golan Y. Current treatment options for acute skin and skin-structure infections. Clin Infect Dis 2019; 68:S206–S212.
Lázaro-Díez M, Remuzgo-Martínez S, Rodríguez-Mirones C, et al. Effects of subinhibitory concentrations of ceftaroline on methicillin-resistant Staphylococcus aureus (MRSA) biofilms. PLoS One 2016; 11:e0147569.
Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 2010; 15:554–563.
Iqbal K, Milioudi A, Wicha SG. Pharmacokinetics and pharmacodynamics of tedizolid. Clin Pharmacokinet 2022; 61:489–503.
Drugbank Online. Dalbavancin. Available at: https://go.drugbank.com/drugs/DB06219 [Accessed 12 December 2022].
Jones RN, Stilwell MG. Comprehensive update of dalbavancin activity when tested against uncommonly isolated Streptococci, Corynebacterium spp., Listeria monocytogenes, and Micrococcus spp. (1357 strains). Diagn Microbiol Infect Dis 2013; 76:239–240.
Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:940–945.
Kresken M, Klare I, Wichelhaus TA, et al. Glycopeptide resistance in Enterococcus spp. and coagulase-negative Staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility. J Glob Antimicrob Resist 2022; 28:102–107.
Hashemian SMR, Farhadi Z, Farhadi T. Fosfomycin: the characteristics, activity, and use in critical care. Ther Clin Risk Manag 2019; 15:525–530.
Mitchell ED, Czoski Murray C, Meads D, et al. Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: Civas systematic review. BMJ Open 2017; 7:e013560.
Candel FJ, Julián-Jiménez A, González-Del Castillo J. Current status in outpatient parenteral antimicrobial therapy: a practical view. Rev Esp Quimioter 2016; 29:55–68.
Chapman AL, Seaton RA, Cooper MA, et al. Good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults in the UK: a consensus statement. J Antimicrob Chemother 2012; 67:1053–1062.
Emilie C, de Nocker P, Saïdani N, et al. Survey of delivery of parenteral antimicrobials in non-inpatient settings across Europe. Int J Antimicrob Agents 2022; 59:106559.
Esposito S, Noviello S, Leone S, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents 2004; 24:473–478.
Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 2020; 9:700.
Gatti M, Andreoni M, Pea F, et al. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Devel Ther 2021; 15:3349–3378.
Scoble PJ, Reilly J, Tillotson GS. Real-world use of oritavancin for the treatment of osteomyelitis. Drugs Real World Outcomes 2020; 7:46–54.
Thomas G, Henao-Martínez AF, Franco-Paredes C, et al. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents 2020; 56:106069.
Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 2018; 67:795–798.
Dryden MS. Alternative clinical indications for novel antibiotics licensed for skin and soft tissue infection? Curr Opin Infect Dis 2015; 28:117–124.
Hornak JP, Reynoso D. Early clinical experience with delafloxacin: a case series. Am J Med Sci 2022; 363:359–363.
Bock M, Theut AM, van Hasselt JGC, et al. Attainment of target antibiotic levels by oral treatment of left-sided infective endocarditis: a poet substudy. Clin Infect Dis 2023; 77:242–251.
Akhter SA, Badami A, Murray M, et al. Hospital readmissions after continuous-flow left ventricular assist device implantation: incidence causes, and cost analysis. Ann Thorac Surg 2015; 100:884–889.
Cagliostro B, Levin AP, Fried J, et al. Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. J Heart Lung Transplant 2016; 35:108–114.
Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. Lancet Infect Dis 2006; 6:426–437.
Hernandez GA, Nunez Breton JD, Chaparro SV. Driveline infection in ventricular assist devices and its implication in the present era of destination therapy. Open J Cardiovasc Surg 2017; 9:1179065217714216.
Hernandez RE, Singh SK, Hoang DT, et al. Present-day hospital readmissions after left ventricular assist device implantation: a large single-center study. Tex Heart Inst J 2015; 42:419–429.
Smedira NG, Hoercher KJ, Lima B, et al. Unplanned hospital readmissions after Heartmate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail 2013; 1:31–39.